Research Article
Outcomes of Anterior Chamber, Sulcus, and Pars Plana Glaucoma Drainage Device Placement in Glaucoma Patients
Table 1
Demographic and ocular dataa.
| | Parameters | Total | AC | S | PP | value |
| | Demographics | | Eyes | 120 | 40 | 40 | 40 | | | Female sex, N (%) | 64 (53.3) | 23 (57.5) | 22 (55.0) | 19 (47.5) | 0.719 | | Age (years) | | | | | <0.001 | | Mean ± SD | 69.8 ± 15.1 | 73.9 ± 11.0 | 72.9 ± 11.7 | 62.6 ± 18.9 | | | Range | 18–92 | 46–92 | 43–87 | 18–90 | |
| | Glaucoma stage, N (%) | | | | | <0.001 | | Mild | 7 (5.8) | 0 (0.0) | 0 (0.0) | 7 (17.5) | | | Moderate | 20 (16.7) | 3 (7.5) | 4 (10.0) | 13 (32.5) | | | Severe | 89 (74.2) | 36 (90.0) | 36 (90.0) | 17 (42.5) | | | Indeterminate | 4 (3.3) | 1 (2.5) | 0 (0.0) | 3 (7.5) | |
| | Glaucoma type, N (%) | | | | | <0.001 | | Aphakic | 1 (0.8) | 0 (0.0) | 0 (0.0) | 1 (2.5) | | | Chronic angle closure | 6 (5.0) | 0 (0.0) | 2 (5.0) | 4 (10.0) | | | Mixed-mechanism | 36 (30.0) | 5 (12.5) | 9 (22.5) | 22 (55.0) | | | Neovascular | 3 (2.5) | 2 (5.0) | 0 (0.0) | 1 (2.5) | | | Normal tension | 1 (0.8) | 1 (2.5) | 0 (0.0) | 0 (0.0) | | | Primary open-angle | 54 (45.0) | 24 (60.0) | 23 (57.5) | 7 (17.5) | | | Pseudoexfoliative | 19 (15.8) | 8 (20.0) | 6 (15.0) | 5 (12.5) | |
| | Mixed-mechanism type, N (%) | | | | | <0.001 | | Traumatic | 10 (8.3) | 2 (5.0) | 0 (0.0) | 8 (20.0) | | | CACG | 15 (12.5) | 2 (5.0) | 5 (12.5) | 8 (20.0) | | | POAG | 13 (10.8) | 2 (5.0) | 4 (10.0) | 7 (17.5) | | | CRVO | 2 (1.7) | 0 (0.0) | 2 (5.0) | 0 (0.0) | | | DM | 1 (0.8) | 0 (0.0) | 1 (2.5) | 0 (0.0) | | | Narrow angles | 2 (1.7) | 0 (0.0) | 1 (2.5) | 1 (2.5) | | | Pigmentary | 3 (2.5) | 1 (2.5) | 1 (2.5) | 1 (2.5) | | | JOAG | 2 (1.7) | 1 (2.5) | 1 (2.5) | 0 (0.0) | | | Steroid response | 9 (7.5) | 2 (5.0) | 0 (0.0) | 7 (17.5) | | | High myopia | 1 (0.8) | 1 (2.5) | 0 (0.0) | 0 (0.0) | | | Postvitrectomy | 2 (1.7) | 1 (2.5) | 1 (2.5) | 0 (0.0) | | | Uveitic | 5 (4.2) | 0 (0.0) | 1 (2.5) | 4 (10.0) | | | NVG | 2 (1.7) | 0 (0.0) | 1 (2.5) | 1 (2.5) | | | ICE syndrome | 1 (0.8) | 0 (0.0) | 1 (2.5) | 0 (0.0) | | | Aniridia | 4 (3.3) | 0 (0.0) | 0 (0.0) | 4 (10.0) | |
| | Lens status, N (%) | | | | | <0.001 | | Phakic | 44 (36.7) | 8 (20.0) | 30 (75.0) | 6 (15.0) | | | Pseudophakic | 71 (59.2) | 32 (80.0) | 10 (25.0) | 29 (72.5) | | | Aphakic | 5 (4.2) | 0 (0.0) | 0 (0.0) | 5 (12.5) | |
| | Prior glaucoma laser, N (%) | | | | | <0.001 | | None | 60 (50.0) | 22 (55.0) | 26 (65.0) | 12 (30.0) | | | ALT | 3 (2.5) | 1 (2.5) | 0 (0.0) | 2 (5.0) | | | LPI | 14 (11.7) | 1 (2.5) | 7 (17.5) | 6 (15.0) | | | LTP | 4 (3.3) | 1 (2.5) | 0 (0.0) | 3 (7.5) | | | MPCPC/CWCPC | 22 (18.3) | 5 (12.5) | 1 (2.5) | 16 (40.0) | | | SLT | 20 (16.7) | 9 (22.5) | 8 (20.0) | 3 (7.3) | | | YAG | 7 (5.8) | 3 (7.5) | 0 (0.0) | 4 (10.0) | | | PRP | 2 (1.7) | 0 (0.0) | 0 (0.0) | 2 (5.0) | | | ECP | 3 (2.5) | 0 (0.0) | 0 (0.0) | 3 (7.5) | |
| | Prior glaucoma surgery, N (%) | | | | | <0.001 | | None | 40 (33.3) | 8 (20.0) | 26 (65.0) | 6 (15.0) | | | Trabeculectomy | 20 (16.7) | 10 (25.0) | 5 (12.5) | 5 (12.5) | | | Tube shunt | 5 (4.2) | 3 (7.5) | 0 (0.0) | 2 (5.0) | | | PEcK, iStent | 2 (1.7) | 1 (2.5) | 0 (0.0) | 1 (2.5) | | | Other (PPV, DSEK, Phaco) | 74 (61.7) | 28 (70.0) | 10 (25.0) | 36 (90.0) | |
|
|
AC = anterior chamber; S = sulcus; PP = pars plana; N = number of eyes; SD = standard deviation; CACG = chronic angle closure glaucoma; POAG = primary open-angle glaucoma; CRVO = central retinal vein occlusion; DM = diabetes mellitus; JOAG = juvenile open-angle glaucoma; NVG = neovascular glaucoma; ICE = iridocorneal endothelial; ALT = argon laser trabeculoplasty; LPI = laser peripheral iridotomy; LTP = laser trabeculoplasty; MPCPC = Micropulse cyclophotocoagulation; CWCPC = continuous wave cyclophotocoagulation; SLT = selective laser trabeculoplasty; YAG = YAG laser capsulotomy; PRP = pan-retinal photocoagulation; PEcK = phacoemulsification with endoscopic cyclophotocoagulation and Kahook dual blade; PPV = pars plana vitrectomy; DSEK = Descemet’s stripping endothelial keratoplasty; Phaco = phacoemulsification. aBaseline demographic and ocular data across the 3 treatment groups were compared using a Fisher test.
|
